Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Naquotinib |
Synonyms | |
Therapy Description |
Naquotinib (ASP8273) is a third-generation EGFR inhibitor that binds mutant forms of EGFR, including T790M, and also inhibits AXL, thus may lead to growth inhibition in tumor cells (PMID: 29467275, PMID: 31092564). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Naquotinib | ASP8273 | AXL Inhibitor 30 EGFR Inhibitor 3rd gen 26 | Naquotinib (ASP8273) is a third-generation EGFR inhibitor that binds mutant forms of EGFR, including T790M, and also inhibits AXL, thus may lead to growth inhibition in tumor cells (PMID: 29467275, PMID: 31092564). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02674555 | Phase I | Naquotinib | A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors | Withdrawn | 0 | |
NCT03082300 | Phase I | Naquotinib | A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations | Terminated | USA | 0 |
NCT02113813 | Phase I | Naquotinib | A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | Completed | USA | 0 |
NCT02588261 | Phase III | Naquotinib Gefitinib Erlotinib | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations | Terminated | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 13 |
NCT03042013 | Phase II | Naquotinib | A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study | Withdrawn | 0 |